Go back

Medicines agency ‘concerned’ about Brexit impact

The executive director of the European Medicines Agency has warned that the organisation’s relocation to Amsterdam from London could have long-term negative consequences.

The EMA’s ability to “keep abreast of scientific and regulatory developments and to support research and development of medicines in Europe” has been “hampered, at least in the short term” by the changes forced on it by Brexit, Guido Rasi said in his introduction to the EMA’s 2018 annual report, published on 3 May.

For example, the agency had to suspend publication of clinical data “just as our landmark policy started to yield the benefits we were expecting from it: enabling reassessment of data, facilitating research collaboration and increasing stakeholders’ trust in the medicine evaluation process”, he said.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.